Home/Filings/3/0001567619-20-020223
3//SEC Filing

Sarissa Capital Master Fund II LP 3

Accession 0001567619-20-020223

CIK 0001659323other

Filed

Nov 22, 7:00 PM ET

Accepted

Nov 23, 5:01 PM ET

Size

19.5 KB

Accession

0001567619-20-020223

Insider Transaction Report

Form 3
Period: 2020-11-22
Holdings
  • 6.500% Exchangeable Senior Subordinated Note due 2025

    (indirect: See footnotes)
    Exercise: $0.78From: 2021-01-21Exp: 2025-01-31Ordinary Shares (19,292,768 underlying)
Holdings
  • 6.500% Exchangeable Senior Subordinated Note due 2025

    (indirect: See footnotes)
    Exercise: $0.78From: 2021-01-21Exp: 2025-01-31Ordinary Shares (19,292,768 underlying)
Holdings
  • 6.500% Exchangeable Senior Subordinated Note due 2025

    (indirect: See footnotes)
    Exercise: $0.78From: 2021-01-21Exp: 2025-01-31Ordinary Shares (19,292,768 underlying)
Holdings
  • 6.500% Exchangeable Senior Subordinated Note due 2025

    (indirect: See footnotes)
    Exercise: $0.78From: 2021-01-21Exp: 2025-01-31Ordinary Shares (19,292,768 underlying)
Holdings
  • 6.500% Exchangeable Senior Subordinated Note due 2025

    (indirect: See footnotes)
    Exercise: $0.78From: 2021-01-21Exp: 2025-01-31Ordinary Shares (19,292,768 underlying)
Holdings
  • 6.500% Exchangeable Senior Subordinated Note due 2025

    (indirect: See footnotes)
    Exercise: $0.78From: 2021-01-21Exp: 2025-01-31Ordinary Shares (19,292,768 underlying)
Footnotes (4)
  • [F1]See Exhibit 99.1
  • [F2]See Exhibit 99.1
  • [F3]See Exhibit 99.1
  • [F4]See Exhibit 99.1

Issuer

Iterum Therapeutics plc

CIK 0001659323

Entity typeother
IncorporatedCayman Islands

Related Parties

1
  • filerCIK 0001811636

Filing Metadata

Form type
3
Filed
Nov 22, 7:00 PM ET
Accepted
Nov 23, 5:01 PM ET
Size
19.5 KB